High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa

Br J Dermatol. 2022 Sep;187(3):417-419. doi: 10.1111/bjd.21066. Epub 2022 May 18.

Abstract

In this case series, ustekinumab therapy demonstrated efficacy in some patients with severe hidradenitis suppurativa previously treated with adalimumab and/or infliximab. Larger prospective studies are needed to evaluate ustekinumab as a treatment option for recalcitrant hidradenitis suppurativa.

Publication types

  • Letter

MeSH terms

  • Adalimumab / therapeutic use
  • Dermatologic Agents* / therapeutic use
  • Hidradenitis Suppurativa* / drug therapy
  • Humans
  • Infliximab / therapeutic use
  • Ustekinumab / therapeutic use

Substances

  • Dermatologic Agents
  • Infliximab
  • Ustekinumab
  • Adalimumab